Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs

Parsippany, N.J. – August 6, 2024 – Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Fabrizio Tondolo as Vice President of Medical Affairs, effective today.

Dr. Tondolo is a distinguished Medical Affairs leader with a proven track record of successful medical and scientific advocacy and the translation of novel science into real-world clinical advances.

As an Executive Committee member reporting to Melinta’s President & CEO, Christine Ann Miller, Dr. Tondolo will be responsible for developing and implementing integrated medical plans for Melinta’s portfolio. Additionally, Dr. Tondolo will help Melinta stand out as a thought leader in the important conversations happening in scientific and medical communities.

“We are thrilled to welcome Fabrizio as Vice President of Medical Affairs at Melinta,” said Christine Ann Miller, President and CEO, of Melinta Therapeutics. “His robust scientific knowledge, extensive experience in people and business management, and unwavering passion for innovation make him an invaluable addition to our team. Fabrizio’s background in the acute care setting and his deep commitment to patient care align perfectly with our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses.”

Dr. Tondolo received his MD degree at the University of Bologna and was a practicing physician before joining Merck in 1995. There, he worked in roles of growing managerial responsibility across different functions including sales, marketing, business development, medical affairs, and different therapeutic areas, with a particular focus on acute care and infectious diseases. In 2020, he was appointed to lead the transition team to set up the medical affairs organization for the spin-off of Organon, where most recently he acted as head of Global Medical Affairs and Outcomes Research.

“I am thrilled to join this incredible team at Melinta, where passion and purpose drive every endeavor,” said Tondolo. “This opportunity to contribute to a company with such a clear vision – that everyone who needs our therapies will receive them – is truly inspiring. I look forward to working with our talented team to advance our mission and make a meaningful impact on patients’ lives.”

About Melinta Therapeutics 

Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit Melinta.com.   

Melinta Media Contact:

Sharon Dilling
sdilling@melinta.com